Showing results (1041-1050 of 5,983) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|November 15, 2011
Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivinKunio Okamoto, Isamu Okamoto, Erina Hatashita, et al.
Molecular Cancer Therapeutics|May 16, 2012
SAR131675, a potent and selective VEGFR-3-TK inhibitor with antilymphangiogenic, antitumoral, and antimetastatic activitiesAntoine Alam, Isabelle Blanc, Geneviève Gueguen-Dorbes, et al.
Molecular Cancer Therapeutics|December 20, 2007
Chemical synthesis and biological evaluation of a NAD(P)H:quinone oxidoreductase-1 targeted tripartite quinone drug delivery systemMilène Volpato, Nathalie Abou-Zeid, Richard W Tanner, et al.
Molecular Cancer Therapeutics|December 20, 2007
Efficacy and tissue distribution of DHP107, an oral paclitaxel formulationJung Wan Hong, In-Hyun Lee, Young Hak Kwak, et al.
Molecular Cancer Therapeutics|December 20, 2007
Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporterChung-Pu Wu, Suneet Shukla, Anna Maria Calcagno, et al.
Molecular Cancer Therapeutics|December 20, 2007
In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2Serena Marchetti, Roos L Oostendorp, Dick Pluim, et al.
Molecular Cancer Therapeutics|January 12, 2008
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalizationAn Claes, Pieter Wesseling, Judith Jeuken, et al.
Molecular Cancer Therapeutics|January 12, 2008
From plasma membrane to cytoskeleton: a novel function for semaphorin 6ASilvia Prislei, Simona Mozzetti, Flavia Filippetti, et al.
Molecular Cancer Therapeutics|January 8, 2017
TAS-116, a Novel Hsp90 Inhibitor, Selectively Enhances Radiosensitivity of Human Cancer Cells to X-rays and Carbon Ion RadiationYounghyun Lee, Shigeaki Sunada, Hirokazu Hirakawa, et al.
Molecular Cancer Therapeutics|April 22, 2014
Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitorsRodrigo Dienstmann, Jordi Rodon, Violeta Serra, et al.
Pageof 599